Eat your peas! Wash your hands! Do your homework! Sounds familiar, right? None of us got to adulthood without following a set of simple rules. Of course, mom was right… Whether you’re a kid or an adult approaching retirement, all of these rules are important.  Especially the homework rule.  Doing your homework, knowing your investments and researching the new ones is a very important and necessary part of being a successful investor.  Worry not, though. If you’re a subscriber to my Daily Paycheck premium income newsletter service, I do the homework for you. Even if you sometimes don’t feel like… Read More

Eat your peas! Wash your hands! Do your homework! Sounds familiar, right? None of us got to adulthood without following a set of simple rules. Of course, mom was right… Whether you’re a kid or an adult approaching retirement, all of these rules are important.  Especially the homework rule.  Doing your homework, knowing your investments and researching the new ones is a very important and necessary part of being a successful investor.  Worry not, though. If you’re a subscriber to my Daily Paycheck premium income newsletter service, I do the homework for you. Even if you sometimes don’t feel like it… Besides researching stocks and funds, my own homework includes a healthy dose of staying on top of all the latest news and studying what others think about the market. Plus, when I can, I also look at what other experienced investors are doing, taking the opportunity to learn from the knowledge and practical experience of others.  But this doesn’t just mean we should blindly take positions in companies other experienced investors like, regardless of how rich and famous those investors happen to be.  —Sponsored Link— New ‘Perfect Retirement Business’ Could Make You $100s Per Week… Read More

Biotech and pharmaceutical stocks have been in the political crosshairs for more than a year. The threat of government controls left the group attractively valued into 2017 but the potential for headline risks has kept most investors on the sidelines.  That is, until last week. Biotech shares jumped last week on rumors of the President’s executive order supporting industry-friendly measures that address drug prices. Prices were also boosted by the industry escaping targeted pricing measures in the Senate’s draft healthcare bill. With the headline risk of regulatory action against pricing all but off the table, shares of drug makers can… Read More

Biotech and pharmaceutical stocks have been in the political crosshairs for more than a year. The threat of government controls left the group attractively valued into 2017 but the potential for headline risks has kept most investors on the sidelines.  That is, until last week. Biotech shares jumped last week on rumors of the President’s executive order supporting industry-friendly measures that address drug prices. Prices were also boosted by the industry escaping targeted pricing measures in the Senate’s draft healthcare bill. With the headline risk of regulatory action against pricing all but off the table, shares of drug makers can finally get back to trading at fair values.  While investors have already started to come back to the group, the market still isn’t fully pricing in leadership or drug pipeline potential.  Biotech Steps Up To Lead The Market The Biotech industry got hammered last year, with several companies spotlighted for triple-digit price increases on drugs and non-stop rhetoric against the industry from both sides of the race for president.  #-ad_banner-#Shares of the SPDR S&P Biotech ETF (NYSE: XBI) plunged 25%, even with the late-year rally after the November election. Investors have been cautiously optimistic this year, noting low valuations… Read More

Not too long ago, I took a cross-country trip to Florida. I had to pick up a few items before departing, and it just so happened that a “Super” Target was right on my way. So, in the name of research and curiosity, I decided to check out the store. It was Thursday, around 6 p.m., a time when my neighborhood supermarket is slammed and the mall is usually busy. (I only know this because I might have a small shopping addiction.) As I walked through the cavernous store, I passed 25 checkout stations that were almost completely devoid of… Read More

Not too long ago, I took a cross-country trip to Florida. I had to pick up a few items before departing, and it just so happened that a “Super” Target was right on my way. So, in the name of research and curiosity, I decided to check out the store. It was Thursday, around 6 p.m., a time when my neighborhood supermarket is slammed and the mall is usually busy. (I only know this because I might have a small shopping addiction.) As I walked through the cavernous store, I passed 25 checkout stations that were almost completely devoid of activity. It felt a little like that Twilight Zone episode where a man finds himself completely alone in a normally bustling town. The lights were on… the music was playing… but there were no shoppers (or employees, for that matter) in sight.  After 15 minutes of strolling along aisles packed with goods designed by B-list TV stars, one thought nagged at my brain.  How is this company still in business? I know that may sound a bit dramatic, but I’ve been following Target (NYSE: TGT) for more than a decade and this has always amazed me.  And not in a… Read More

“Three dollars for a cup of coffee, I would short that stock now!” said the grizzled old stock trader at the 1992 IPO of the coffee chain.  Believing that high-priced coffee and a company that encourages customers to hang out in a relaxed atmosphere was nothing but a fad, the market veteran, like many investors of his time, saw only a bleak future for Starbucks (Nasdaq: SBUX).   As we all know, the shorts were crushed as SBUX exceeded all expectations. A $100,000 investment at the IPO price of $17.00 per share would have grown to over $10… Read More

“Three dollars for a cup of coffee, I would short that stock now!” said the grizzled old stock trader at the 1992 IPO of the coffee chain.  Believing that high-priced coffee and a company that encourages customers to hang out in a relaxed atmosphere was nothing but a fad, the market veteran, like many investors of his time, saw only a bleak future for Starbucks (Nasdaq: SBUX).   As we all know, the shorts were crushed as SBUX exceeded all expectations. A $100,000 investment at the IPO price of $17.00 per share would have grown to over $10 million when splits and dividends are taken into consideration. That’s an amazing return no matter how you look at it.  But the question on every investor’s mind is what does the future hold for the stock? Has the company reached its potential or will the outsized performance continue long into the future?  The World’s Coffee Shop As I sit here in Starbucks writing this article, I can’t help but marvel at the steady stream of customers that has fueled an incredible growth story.  #-ad_banner-#The coffee chain has become a behemoth, with 26,000 stores spread across 75 countries that employ… Read More

Over the last decade, we’ve published thousands of in-depth research reports. Everything from high dividend payers, game-changing innovations, top stocks in emerging markets — you name it, we’ve told you how to profit from it.  But the research I’m going to tell you about today stands head and shoulders above everything else we’ve ever done.  In fact, it ranks as our single most popular report of all time. We call it: Our Ultimate “Forever Stocks.” —Recommended Link— $43K A Year For Life… (Takes 20 Minutes) Want an extra $43,543 a year in bonus income? You need to see this…… Read More

Over the last decade, we’ve published thousands of in-depth research reports. Everything from high dividend payers, game-changing innovations, top stocks in emerging markets — you name it, we’ve told you how to profit from it.  But the research I’m going to tell you about today stands head and shoulders above everything else we’ve ever done.  In fact, it ranks as our single most popular report of all time. We call it: Our Ultimate “Forever Stocks.” —Recommended Link— $43K A Year For Life… (Takes 20 Minutes) Want an extra $43,543 a year in bonus income? You need to see this… And fast. It shows the five simple steps to take to start collecting this money. Your checks should start coming in within a month… And continue to roll in forever. You can even pass your payments on to your heirs… And they can collect the money after you’re gone. It’s all here. And you can get set up in 20 minutes.  You’ve probably heard us talk about the idea of “Forever Stocks” before. Simply put, these are solid companies that we think you can feel confident buying and holding onto for years, even decades.  And we believe they will continue… Read More

Big tech is having another monster year. The big four technology leaders, also known as FANG — Facebook, Amazon, Netflix, and Google (Alphabet) — have returned an average of 29% in 2017. Take a look at the chart below. This basket of tech high flyers has been great for growth investors, crushing the S&P 500’s 9% return in 2017.  However, for income investors, these outsized gains have been painful to watch. Most of the FANG stocks don’t pay a dividend. And watching this group of stocks deliver a 29% gain in less than six months can make a… Read More

Big tech is having another monster year. The big four technology leaders, also known as FANG — Facebook, Amazon, Netflix, and Google (Alphabet) — have returned an average of 29% in 2017. Take a look at the chart below. This basket of tech high flyers has been great for growth investors, crushing the S&P 500’s 9% return in 2017.  However, for income investors, these outsized gains have been painful to watch. Most of the FANG stocks don’t pay a dividend. And watching this group of stocks deliver a 29% gain in less than six months can make a normally impressive 5% dividend yield seem insignificant. But don’t worry, I have the perfect solution for income investors looking for a piece of tech growth — a well-known global leader that I consider to be the best growth and income stock in the S&P 500. This global leader is still delivering outsized sales and earnings growth. It offers one of the best dividend yields in the technology sector and one of the fastest growing dividends in the S&P 500. And even better, compared to FANG stocks it looks undervalued. Microsoft (Nasdaq: MSFT) is one of the greatest growth stocks in… Read More